NewsRoom Articles - BioMedWire (BMW)

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

TuesdayJun 23, 2026 10:00 am

WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma. The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat. The study, whose findings appeared in Nature Cancer, sought to test a novel DNA platform that designs a personalized vaccine aimed at preventing glioblastoma tumors from recurring. Glioblastoma grows aggressively and patients rarely survive for more than a year or two after diagnosis, and scientists have been racing to develop new treatments that…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…

MondayJun 22, 2026 10:00 am

Why Men Need Sexual Health Help While Undergoing Cancer Treatment

About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated for different kinds of cancer suffer a degree of sexual dysfunction or erectile challenges. Most hardly ever open up about these issues and they suffer in silence. This needn’t be so, because there are many ways through which sexual challenges can be addressed for men with cancer. Cancer treatment is taxing on the body. For example, radiation and chemotherapy can leave patients feeling nauseous and fatigued, which can affect sexual performance. Surgical procedures like those undertaken to manage prostate cancer can also damage nerves, causing sexual problems to arise. Most men don’t receive adequate sexual education…

MondayJun 22, 2026 9:00 am

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited…

MondayJun 22, 2026 9:00 am

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by…

MondayJun 22, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection

The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets. Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of…

ThursdayJun 18, 2026 10:30 am

Earth Science Tech Inc. (ETST) Signals Strong Confidence with Aggressive Q1 Share Buybacks

Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reflects management’s growing internal confidence in the company’s future trajectory. Over 3 million shares of common stock have been repurchased in current fiscal quarter, a significant acceleration in buybacks. Reduction in share dilution can consolidate existing equity and potentially boost earnings per share (“EPS”). Earth Science Tech (OTC: ETST) is capturing the attention of the micro-cap market following a significant acceleration of its share repurchase program. Recent market data indicates that the company is aggressively buying back its own…

ThursdayJun 18, 2026 10:00 am

CMS Issues Final Rules on Medicaid Eligibility Work Requirements

Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue final rules on those work requirements. The federal agency has since published those final rules and enrollees on the Medicaid program need to acquaint themselves with these requirements to ensure they comply in order to retain their eligibility. We discuss some of those requirements. The rules, published on June 1, aren’t going to affect every person enrolled on Medicaid. Instead, they will affect individuals whose coverage is in the category of Medicaid expansion. This program is offered in some, but not all, states around the country. Under Medicaid expansion, adults who earn a low income…

ThursdayJun 18, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Launches Lead Commercial Software Intox AI(TM) for Multiple Forms of Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The platform is designed to detect cocaine, cannabis, alcohol, narcotics, psychedelics, and human fatigue using voice analysis and artificial intelligence. MindBio is preparing to deploy the software through Edge AI kiosk systems targeted at safety-critical industries. The company is pursuing commercialization opportunities in mining, aviation, construction, transportation, and law enforcement markets. MindBio’s technology offers a non-invasive and affordable alternative to traditional drug and alcohol testing methods. The launch represents a key step in the company’s transition from research and clinical development toward commercial implementation. MindBio Therapeutics…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

Why Men Need Sexual Health Help While Undergoing Cancer Treatment

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

HeartBeam Inc. (NASDAQ: BEAT) Launches Study Focused on Testing Proprietary Patch Capable of Generating On-Demand 12-Lead ECG for Ischemia Detection

Earth Science Tech Inc. (ETST) Signals Strong Confidence with Aggressive Q1 Share Buybacks

CMS Issues Final Rules on Medicaid Eligibility Work Requirements

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Launches Lead Commercial Software Intox AI(TM) for Multiple Forms of Intoxication Detection

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search